Contrast ultrasonography and CEUS LI-RADS standard classification of DN-HCC and DN patients were observed

Abstract

Abstract: Objective To investigate the contrast-enhanced ultrasound (CEUS) findings and the standard classification results of CEUS liver image reporting and data system (CEUS LI-RADS) in patients with dysplastic nodules with focal hepatocellular carcinoma (DN-HCC) and dysplastic nodules (DN). Methods 78 patients with hepatic focal lesions (80 lesions, including 12 DN and 68 DN-HCC) admitted to our hospital between October 2019 and October 2021, and all patients underwent CEUS examination. All lesions were classified according to CEUS Li-RADS V2017 criteria. Results The proportion of synchronous enhancement in arterial phase in DN group was 66.7%, which was significantly higher than 13.2% in DN-HCC group (P<0.05); The proportion of high enhancement in arterial phase in DN group was 16.7%, which was significantly lower than 58.8% in DN-HCC group (P<0.05). In the DN group, there were three CEUS enhancement modes in arterial phase and delayed phase, of which low / equal accounted for 25.0%, equal/equal accounted for 66.7%, and high / high accounted for 8.3%;There were six CEUS enhancement modes in dn-hcc group, of which equal/equal accounted for 4.4%, low / low accounted for 5.9%, equal/low accounted for 8.8%, low/equal accounted for 13.2%, high (including local high enhancement) / low accounted for 29.4%, and high (including local high enhancement)/equal accounted for 38.2%. The proportion of LR-3 in CEUS LI-RADS v2017 standard classification in DN group was 100.0%, which was higher than 26.5% in DN-HCC group (P<0.05).Conclusion CEUS arterial phase high enhancement or delayed phase decline has differential significance between DN and DN-HCC, which is worthy of clinical verification.

Key words: Dysplastic nodule, Focal hepatocellular carcinoma, Contrast enhanced ultrasound, Liver imaging reporting and data system

SHI Xu, QIAO Xiang-bin, LIU Jia, XIAO Bao-jun. Contrast ultrasonography and CEUS LI-RADS standard classification of DN-HCC and DN patients were observed[J]. Chinese Hepatolgy, 2023, 28(1): 79-82.

References

[1] Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol, 2019, 70(4):674-683.
[2] Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019, 156(2):477-491.
[3] 李小娟, 黄品同, 徐永远, 等. 超声造影肝影像报告和数据系统与磁共振肝影像报告和数据系统对肝细胞癌高危患者肝占位性病变的一致性评价研究. 中华超声影像学杂志, 2020, 29(6):522-528.
[4] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[5] 高芬, 蔡萍, 刘晨, 等. 肝细胞癌癌前结节影像学特征的研究进展. 中华肝脏病杂志, 2020, 28(1):9-13.
[6] Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol, 2014, 109(9):1328-1347.
[7] Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med, 2013, 34(1):11-29.
[8] Kono Y, Lyshchik A, Cosgrove D, et al. Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS): the official version by the American College of Radiology (ACR). Ultraschall Med, 2017, 38(1):85-86.
[9] 丁建民, 龙磊, 周洪雨, 等. 超声造影肝脏影像报告与数据系统对高危人群肝细胞癌的风险预测. 中华超声影像学杂志, 2020, 29(2):138-142.
[10] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3):145-151.
[11] Joo I, Kim SY, Kang TW, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology. 2020, 296(2):335-345.
[12] Liu D, Liu F, Xie X, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol, 2020, 30(4):2365-2376.
[13] Ainora ME, Iezzi R, Ponziani FR, et al. Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment. Dig Dis, 2020, 38(6):522-533.
[14] 陈彦玲, 王文平. 超声造影在肝细胞性肝癌诊疗中的应用进展. 中华超声影像学杂志, 2020, 29(10):916-920.
[15] Duan Y, Xie X, Li Q, et al. Differentiation of regenerative nodule, dysplastic nodule, and small hepatocellular carcinoma in cirrhotic patients: a contrast-enhanced ultrasound-based multivariable model analysis. Eur Radiol, 2020, 30(9):4741-4751.
[16] Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67(9):1674-1682.
[17] Fan PL, Xia HS, Ding H, et al. Characterization of early hepatocellular carcinoma and high-grade dysplastic nodules on contrast-enhanced ultrasound: correlation with histopathologic findings. J Ultrasound Med, 2020, 39(9):1799-1808.
[18] Wu W, Chen M, Yan K, et al. Evaluation of contrast-enhanced ultrasound for diagnosis of dysplastic nodules with a focus of hepatocellular carcinoma in liver cirrhosis patients. Chin J Cancer Res, 2015, 27(1):83-89.
[19] Park HJ, Choi BI, Lee ES, et al. How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer, 2017, 6(3):189-203.